Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corcept Therapeutics

71.24
-0.6100-0.85%
Volume:907.29K
Turnover:65.06M
Market Cap:7.55B
PE:62.36
High:73.13
Open:72.04
Low:70.78
Close:71.85
Loading ...

Is Corcept Therapeutics (CORT) Outperforming Other Medical Stocks This Year?

Zacks
·
28 Feb

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 48% Above Its Share Price

Simply Wall St.
·
28 Feb

Why Corcept (CORT) Shares Are Sliding Today

StockStory
·
28 Feb

Stock Track | Corcept Therapeutics Plunges 5.51% as Delayed Ovarian Cancer Study Timeline Disappoints Investors

Stock Track
·
28 Feb

CORT's Q4 Earnings and Revenues Fall Short of Estimates

Zacks
·
27 Feb

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

Zacks
·
27 Feb

Stock Track | Corcept Therapeutics Plunges 5.32% in Pre-Market as Ovarian Cancer Study Timeline Disappoints

Stock Track
·
27 Feb

Q4 2024 Corcept Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
27 Feb

Corcept Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
27 Feb

Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?

Zacks
·
27 Feb

Corcept Therapeutics: Strong Financial Outlook and Promising Clinical Developments Support Buy Rating

TIPRANKS
·
27 Feb

Corcept Therapeutics Inc (CORT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com
·
27 Feb

Corcept Therapeutics Reports Strong 2024 Financial Growth

TIPRANKS
·
27 Feb

Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates

Zacks
·
27 Feb

Corcept: Q4 Earnings Snapshot

Associated Press Finance
·
27 Feb

Corcept Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

Corcept Q4 Net Income Lower, Revenue Rises; Sets Guidance

MT Newswires Live
·
27 Feb

Corcept Therapeutics Q4 2024 GAAP EPS $0.26 Misses $0.42 Estimate, Sales $181.900M Miss $198.686M Estimate

Benzinga
·
27 Feb

BRIEF-Corcept Therapeutics Q4 EPS USD 0.26 Vs. IBES Estimate USD 0.43

Reuters
·
27 Feb

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update

Business Wire
·
27 Feb